Related Experiment Video
Updated: Jun 27, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Telbivudine in the treatment of chronic hepatitis B
Stephanos J Hadziyannis1, Dimitrios Vassilopoulos
1Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 115 26 Athens, Greece. hadziyannis@ath.forthnet.gr
Abstract:
Treatment of chronic hepatitis B with oral nucleos(t)ide analogs is evolving rapidly with newer compounds gaining approval. Recently, the US FDA and European Medicines Agency (EMEA) have approved telbivudine, a potent anti-hepatitis B virus (HBV)-specific agent with a hitherto excellent safety profile. This review focuses on the efficacy of this agent in chronic hepatitis B compared with lamivudine, evaluated clinically in Phase II and a large Phase III study. Monitoring of the virologic response under treatment with sensitive HBV-DNA assays has been applied, aiming at increasing efficacy and reducing HBV resistance. The results are critically presented and the evolving concept of effective long-term telbivudine and other nucleos(t)ide analog therapy, predicted by the extent of suppression of HBV replication at week 24, are analyzed and discussed.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Inhibitors Of Virion Release
